Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
Title:
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
Author:
Musacchio, Lucia Salutari, Vanda Pignata, Sandro Braicu, Elena Cibula, David Colombo, Nicoletta Frenel, Jean Sebastien Zagouri, Flora Carbone, Vittoria Ghizzoni, Viola Giolitto, Serena Giudice, Elena Te Perri, Maria resa Ricci, Caterina Scambia, Giovanni Lorusso, Domenica
Appeared in:
International journal of gynecological cancer
Paging:
Volume 31 () nr. 10 pages 1369-1373
Year:
2021
Contents:
Publisher:
IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.